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Abstract 
Background: Tuberculosis (TB) continues to be one of the major causes of illnesses and 
deaths worldwide. Currently, it is estimated that about one-third of the world population is 
infected with TB. Early effective diagnosis and treatment are crucial to reduce mortality, 
morbidity and transmission of TB. Tuberculin skin test (TST) has been widely used as a 
screening test for TB and has contributed substantially for generating valuable 
epidemiological information on infection trends and on the magnitude of disease. 
Tuberculosis low incidence countries of Western Europe and USA use TST for screening TB 
among migrant population from high endemic countries of Africa and Asia. For example, it is 
a normal procedure for students from TB endemic countries coming to Norway to undergo 
TST, and skin induration of ≥10mm is considered positive for infection.  However, it is not 
well established that skin induration of ≥10mm is an indication of clinical disease, infection, 
or exposure to environmental mycobacteria in TB high endemic countries such as Ethiopia. 
Therefore, the objective of this study was to compare the size of TST indurations in 
individuals with active TB, their household contacts and community controls and to optimize 
the cut-off point for the diagnosis/ suspecting of active TB in endemic setting, Ethiopia.  
Methods:  In a health facility-based cross-sectional study, smear positive pulmonary TB 
(PTB) patients were recruited consecutively from selected health institutions, whereas their 
household contacts were traced back using the index cases. Community controls were also 
selected randomly from households neighboring index cases. Sputum was collected from all 
patients for AFB staining and culture.  Provider initiated HIV testing and counseling was done 
for all participants and participants who were negative for HIV infection were included.  
Participants were also tested by TST and QuantiFERON®-TB Gold In 
 –Tube test (QFT-GIT). In addition, chest X-ray was done for   household contacts and 
community controls with TST results ≥ 10mm.  
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Results: a total of 224 study participants, 50 smear positive PTB patients, 96 household 
contacts   and 78 community controls were included in this study. All smear positive PTB 
patients who had skin test results (n= 48) had skin test induration ≥10mm, while 44(91.7%) 
had skin test induration ≥ 15 mm.   Among 88 household contacts who had skin test results, 
64 (72.2%) had skin test induration ≥10mm, while 58(65.9%) had skin induration ≥ 15 mm.  
Among 75 community controls who had skin test results, 35 ( 46.7%) had skin test induration 
≥ 10 mm , while 26(34.7%) had skin test induration ≥ 15 mm.  The mean size of TST 
induration was significantly higher in TB patients (18.1mm) compared to that of household 
contacts (13.6 mm) and community controls ( 7.9 mm) (p< 0.001).. The mean size of skin test 
induration was higher in individuals who had BCG scar compared to individuals without 
BCG scar in household contacts and community controls (p< 0, 05).  Among 44 TB patients 
who had QFTGIT results, 36 (81.8%) had ≥ 0.35 IU/ml of IFN- level.  Out of 91 household 
contacts and 58 community controls who were tested by QFTGIT, 64(70, 3%) and 32(55.2%) 
had ≥ 0.35 IU/ml of IFN level, respectively.  The mean level of IFN- was 4.68 IU/ml in TB 
patients, 4.90 IU/ml in contacts and 2.62 IU/ml in community controls. The difference in the 
mean level of IFN- in TB patients and community controls as well as in household contacts 
and community controls were also significant (p<0.05). The mean level of IFN- did not 
differ by BCG status or by socio-demographic characteristics of the study participants.  .  
 Using sputum culture as a reference test skin test induration ≥ 10 mm was found to be 100% 
sensitive in identifying TB patients, while the sensitivity was 91.7% at skin test induration ≥ 
15 mm.  Considering QFT-GIT as reference  test in contacts,  at skin test indurations ≥ 8mm, 
10mm, 11mm and 15 mm, the sensitivities  were found to be 95%, 91.7%, 83.3% and 81.7% , 
respectively, while the specificity was  68% in all cases.  In community controls, at skin test 
indurations ≥ 10 mm and 15 mm, the sensitivities were found to be 81.3% and 65.6%, 
12 
 
respectively, while the respective specificities were 80.8%, 88.5% and 100%.  Among 40 
household contacts who had chest X-ray results, 2(5%) were found to be active TB cases. 
Conclusion: To our knowledge, this is the first study to compare TST skin induration in 
culture confirmed pulmonary TB patients, household contacts, and community controls in 
Ethiopia. The majority (91.7%) of smear positive TB patients had skin test induration ≥ 15 
mm. Moreover, the specificity of the TST was found to be 100% at skin test induration ≥15 
mm in community controls who had no known exposure to TB. Since, a test with high 
specificity is more useful in areas with a high prevalence of disease, skin test induration ≥ 15 
mm seems to be optimal for suspecting active TB and recommending chest X-ray in 
individuals without symptoms suggestive of active TB, while skin test induration ≥ 10 mm 
seems optimal to suggest Mtb infection in household contacts of TB patients. 
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Chapter 1: Introduction  
1.1. Ethiopia: Country Profile 
1.1.1. Population and Demography 
Ethiopia is one of the two African countries that were able to maintain their independence 
from colonial rule. The country is the second most populous  in Africa with an estimated 
population of 93million (1), and is located in the Horn of Africa sharing borders with Kenya 
in the South,  Somalia and Djibouti in the East, Eritrea in the North and Northeast and south 
Sudan and Sudan in the Northwest (fig 1). It has an estimated total area of 1.104 million 
square kilometers (1million sq. kilometers of land area and 104,300 sq. km of water area). 
The country has diverse ethnic groups but the four major ones are Oromo (34.5%), Amhara 
(26.9%), Somali (6.2%) and Tigre (6.1%). The majority of the population (83%) live in the 
rural areas. About 62% of Ethiopians are Christians in religion, whereas 34% are Muslims 
and the remaining follow different religions (1). 
Economically, Ethiopia depends mainly on agriculture, which accounts for around 50% of 
GDP and more than 80% of total employment. Coffee has been a major export agricultural 
product. The agricultural sector suffers from poor cultivation practices and periodic drought, 
but recent joint efforts by the Government of Ethiopia and donors have strengthened 
Ethiopia's agricultural resilience, contributing to a reduction in the number of Ethiopians 
threatened with starvation. To some degree, the economy depends also on animal husbandry. 
Ethiopia is still one of the poorest countries in the world, although the country experiences 
rapid economic development in recent years (1).  
14 
 
 Map of world
   
Figure 1.  Map of Ethiopia 
1.1.2. Ethiopia: Health profile 
Ethiopia’s health problems are predominantly preventable communicable diseases (73.6%) 
which are mainly due to poor sanitation, malnutrition and lack of knowledge. But, the main 
reason why this country is suffering from these types of problems is the low socio-economic 
status of the country. Non communicable diseases (20.1%) such as diabetes mellitus, 
hypertension, cardiac diseases, and cancer diseases are also becoming more common and 
putting the country at double burden .Health-related problem is much higher in cities 
compared to that of rural areas where health services are less accessible (2,3). 
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The most common deadly infectious diseases in this country are malaria, TB and HIV/AIDS. 
These diseases cause a huge impact on the country’s economic growth both in terms of human 
resources and material supply. While TB remains one of the most important diseases in 
Ethiopia, malaria is endemic in two-third of the country`s regions.   The third common and 
most deadly disease in Ethiopia is HIV/AIDS which has taken the life of many Ethiopians 
since the first cases of HIV/AIDS were reported in 1988 (4) and also left many without care 
and support.   
1.1.3. Tuberculosis  
Tuberculosis (TB) is an infectious bacterial disease caused by the Mycobacterium 
tuberculosis Complex (MTC) including Mycobacterium tuberculosis, M. bovis, M. Africanum, 
M. Canetti, and M. microti. However, Mtb is the most common cause of TB in humans. 
Transmission occurs from person to person via droplets from the throats and lungs of people 
with active PTB. In case of bovine TB, transmission occurs through drinking of unpasteurized 
milk (5). Symptoms like fever, night sweat, fatigue, and weight loss are seen in a majority of 
TB patients, but the clinical presentation usually depends on the organs involved: for example 
patients with PTB usually have cough and chest pain (5). 
TB infection starts by the time the bacteria reach the alveoli, where they will quickly be 
surrounded and engulfed by alveolar macrophages. This phagocytic action of macrophages 
together with other cascade of events results either in successful control of the infection, or 
progression to an active TB. As a result of cellular response, granuloma formation occurs, 
which prevents the dissemination of infection (5, 6). 
1.1.4. Epidemiology 
 Globally, it is estimated that more than two billion people are Mtb infected though about 5-
10% of these infected individuals develop active TB disease in their life time. The risk is 
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higher in those who have other additional health problems such as HIV/AIDS, diabetes 
mellitus and malnutrition (7).  
 According to the 2012 WHO report on TB, the global estimated total number of new TB 
cases in 2011 was 7.8 million  (13% co-infected with HIV).  The mortality related to TB for 
the same year was estimated to be 1.4 million people (around one million in those without 
HIV/AIDS and 430000 people million among HIV/AIDS patients (8). More than 90% of TB 
cases and deaths due to TB occur in developing countries and 75% of the affected belong to 
the economically productive age group (15-54 years). Therefore, TB imposes huge economic, 
social and demographic impacts globally (9). In 1993 TB was declared a global emergency, 
and one of the WHO Millennium Development Goal ( MDG) targets is to reduce transmission 
of TB  by 50% by the year 2015 (3, 5). According to the WHO report of 2012 (8) it was stated 
that the world is in progress to achieve the global target of a 50 % reduction by 2015. The 
number of new cases and deaths are falling in all WHO’s six regions and in most of the 22 
high burden countries that accounts for more than 80% of world’s TB cases.  Of course, the 
global burden remains enormous, but the effort to halt or reduce TB is encouraging.  One of 
the main tools to combat TB is the Directly Observed Therapy Short-course (DOTS) strategy 
which includes five elements: 1) political commitment, 2) case detection by sputum 
microscopy, 3) standardized treatment directly observed, 4) Regular supply of essential TB 
drugs, and 5) Regular recording and reporting. This strategy is meant to increase case 
detection, cure rate and avoid resistance. However, this strategy didn’t work as expected due 
to the following factors:  poor public health infrastructures in resource limited countries (10, 
11), failure in early case detection and treatment of TB, emergence of multi-drug resistance 
(MDR) (12) and the impact of HIV/AIDS (13, 14). 
Delay in the diagnosis and treatment can worsen the disease, prolong the period of 
transmission of TB in the community and subsequently increases the risk of death (15). It has 
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been shown that a patient with untreated smear positive PTB on average can infect more than 
10 people annually and 20 during the natural course of untreated TB until death (16).  
It is well known that HIV/AIDS accelerates both the development of active TB (by 30 times) 
and death due to TB significantly. Globally, about 34 million people are living with HIV and 
it is estimated that one third of them are infected with Mtb. The dual epidemics of TB and 
HIV are particularly significant in Africa, contributing to the increasing incidence of TB over 
the last ten years. In some African countries including Ethiopia, around 50 percent of patients 
with active TB are HIV-positive (16).  Africa accounts for 11 % of the world population, but 
carries 29% of the global TB burden and 34% of deaths related to TB (17, 18).  
1.1.5. Tuberculosis in Ethiopia 
Ethiopia is one of the world’s 22 high burden TB countries that contribute to 82% of the 
global burden of TB.  According to the report of WHO 2012, Ethiopia is the third heavily 
affected country in Africa. The incidence rate of TB in Ethiopia in the same year was 258 
cases per 100,000 pop (8).   DOTS was first introduced by WHO in the early 1990s and 
introduced in Ethiopia in 1992 for effective control of TB. According to a 2009 WHO report, 
only 60 to 70 % of Ethiopians had access to DOTS services, even though DOTS had an 
official’s geographical coverage of 95% (16). Currently, the geographical coverage of DOTs 
is 100%, while the health facility coverage is 95%.  Limited health infrastructure and 
integration of TB control service with other programs were among the reasons contributing to 
the low access of DOTS in Ethiopia. 
Globally, the target for TB control is to detect at least 70% of the smear-positive cases and 
cure at least 85% of the detected cases.  Failure to detect active TB cases at early time, will 
lead to continued spread of infection among the healthy population and as a result many 
people will continue to suffer and /or die of it. The 2011 WHO report on tuberculosis in 
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Ethiopia, has shown that  case detection rate for all new cases of TB was estimated to be 72%,  
and the case detection rate for new smear positive TB was 47%. Although detection of smear 
positive TB cases remains very low, there is some improvements when compared with that of 
the 2009 report. In 2009, the detection rate was 48 % for all forms of TB cases and 34% for 
new smear positive TB cases.  In that case, Ethiopia is still far from attaining the target set by 
WHO and at the same time many TB cases remain undetected and thus untreated, creating 
more chances for TB spread in the community. On the other hand, treatment success rate in 
the same year was 84% which was almost equal to that of the WHO target (85%) (19). Detail 
information about current status of tuberculosis in Ethiopia has been summarized in table 1. 
Table 1. Current status of tuberculosis in Ethiopian 
Estimates of TB burden 2011           Number (thousands)           Rate (per 100 000 pop) 
Mortality (excludes HIV+TB)  15 (11–20)              18 (14–24) 
Prevalence (includes HIV+TB)                 200 (160–240)             237 (191–288) 
Incidence (includes HIV+TB)   220 (160–280)    258 (191–335) 
Incidence (HIV+TB)     38 (28–49)       45 (33–58) 
Case detection, all forms (%)   72 (55–96) 
TB case notifications 2011 
New Cases                                    (%)                Retreatment Cases                    (%) 
Smear-positive         49 594 (32)     Relapse                        2 143    (46) 
Smear-negative        52 967  (34)      Treatment after failure           658      (14) 
Smear-unknown/not done  2 530 (2)   Treatment after default  492      (11) 
Extra-pulmonary   49 305 (32)     Other             1 328    (29) 
Other     0 (0) 
Total new    154 396     Total retreatment       4 621 
Other (history unknown)  0 
Total new and relapse 156 539     Total cases notified        159 017 
New cases    2011 
                                   Smear-Positive          Smear-Negative          Extrapulmonary 
M:F ratio                            1.2 
Age < 15                 3 830     6 025    6 617 
Laboratories         2011 
Smear (per 100 000 population)      2.3 
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Culture (per 5 million population)      0.1 
Drug susceptibility testing (per 5 million population)           <0.1 
Is second-line drug susceptibility testing available?         Yes, in country 
Is there a national reference laboratory?     Yes 
Treatment success rate 2010      (%) 
New smear-positive        83  
New smear-negative/extrapulmonary     75 
Retreatment          83 
 Is rifampicin used throughout (and/or culture-positive) treatment for new patients? Yes 
TB/HIV 2011              Number  (%) 
TB patients with known HIV status                 65 140 (41) 
HIV-positive TB patients                  5 442  (8) 
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)  3 348  (62) 
HIV-positive TB patients on antiretroviral therapy (ART)              2 123  (39) 
HIV-positive people screened for TB         174 146 
HIV-positive people provided with IPT         30 816 
Estimates of MDR-TB burden 2011    New  Retreatment 
% of TB cases with MDR-TB       1.6 (0.86–2.7)  12 (5.6–21) 
MDR-TB cases among notified pulmonary TB cases   1 700 (910–2 900)  550 (260–980) 
Reported cases of MDR-TB 2011   New   Retreatment    Total 
Cases tested for MDR-TB    73 (<1%)  139 (3%)  212 
Laboratory-confirmed MDR-TB cases 35   85   212 
Patients started on MDR-TB treatment      199 
Financing TB control      2012     2013 
Total budget (US$ millions)       50    52 
Available funding (US$ millions)     42    13 
% of budget funded       83    25 
% available funding from domestic sources    20 
% available funding from the Global Fund    48    100 
World Health Organization: The 17
th
 of global tuberculosis control report 2012 
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1.2. Literature Review  
1.2.1. Diagnosis of Tuberculosis 
Early diagnosis and treatment are crucial to reduce TB transmission, which of course 
demands effective diagnostic tests that can detect TB at its early stage (20, 21). Because of the 
infectious nature of pulmonary tuberculosis, fast and accurate diagnosis is a very important 
element of TB control measures (22). In addition, identification of persons with latent TB 
infection, especially those who are at higher risk of progression to active disease, and wider 
use of preventive treatment is necessary to reduce the burden of TB. This also ensures 
successful cure rate, less suffering and a better health for the individuals with TB and the 
whole society. Therefore, identification of people with latent TB infection is very important 
for the control of TB. This can be done effectively through screening Mtb infection with main 
focus on detecting persons with latent TB infection or with active TB disease to offer them 
preventive or standard treatment so that further transmission can be avoided. There are 
different investigative modalities for the diagnosis of TB as a supplement to the clinical 
findings. Some of the tests are intended to detect the bacilli directly (AFB, Culture, and 
molecular amplification techniques) whereas some of them indirectly indicate the presence of 
the bacilli (TST and Interferon Gamma Release Assays (IGRAs)). TST and IGRAs are the 
currently available tests, mainly for the screening of latent TB infection and also aid for the 
diagnosis of active TB.  Many countries in the world still rely on the TST for the 
identification of latent TB infection (23).  The importance and limitations of each test has 
been reviewed below with more focus on IGRAs and TST. 
1.2.2.1. Radiology 
Chest X-ray is widely used for the diagnosing of PTB. But, there is no radiological finding 
typical for TB. Many lung diseases can have similar radiological findings mimicking PTB (5). 
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Moreover, it cannot differentiate active TB from inactive or cured TB. Radiological findings 
of PTB in immune-compromised patients (HIV/AIDS) are variable because the findings are 
different (atypical) from what is normally seen in immunologically competent PTB patients 
(5). Moreover, it can sometimes appear entirely normal especially at early stage of the 
disease. In addition to its poor specificity, it is expensive and requires well experienced 
radiologist to read it. Therefore, X-ray should preferably be utilized as a supportive tool, 
especially in the diagnosis of primary and smear negative PTB (5). 
1.2.2.2. Sputum Microscopy (AFB) 
This is a relatively simple, rapid and inexpensive test among the currently available tests 
utilized for the detection of Mtb and other acid fast bacilli (AFB). It has been used as a 
standard diagnostic method for PTB worldwide, especially in low to middle income countries 
where about 90% of TB cases are found. Smear microscopy has specificity over 95% in a 
high prevalence setting, but the sensitivity is variable, ranging from 40-80%. Sensitivity is 
even much lower in the case of co-infections with HIV, childhood B where sputum yield is 
very low, and in the case of extra-PTB (24). High bacterial load per ml of sputum (5000-
10000/ml) is needed and it requires good training and constant supervision of the laboratory 
technicians (24, 25).   
1.2.2.3. Mycobacterium Culture Method 
 Culture is a gold standard in the diagnosis of active TB compared to other diagnostic tests It 
is more sensitive than sputum smear microscopy. Its sensitivity is around 80-93% but the 
specificity is almost the same as that of sputum smear microscopy (26). Unlike smear 
microscopy, which needs a large number of bacilli to identify the Mtb, culture requires only 
10-100 bacilli per milliliter of specimen to detect TB bacilli (26). Culture can be performed 
either on solid media (Lowenstein-Jensen) or liquid media (Middle brook 7H9 broth) (5, 25). 
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But this method suffers from long recovery time (up to 8weeks) and risk of contamination. 
Some newly developed liquid media methods like microscopic observation drug susceptibility 
(MODS) test requires shorter time (< 2weeks) (27). Contamination is also a substantial 
problem even in high income countries. Culturing generally requires skilled manpower, 
advanced laboratory facilities, and is also expensive (5, 24).  
1.2.2.4. Histopathological Methods 
Histological specimens are important for the diagnosis of extra PTB (for example intestinal 
TB, TB lymphadenitis).The hallmark is to look for the presence of chronic granulomatous 
inflammation in a person suspected to have TB. However, this method is nonspecific because 
many other diseases can also show the same feature. Moreover, it involves invasive 
procedures, requires highly skilled personnel (pathologist), and it is often difficult to access 
the diseased organs (internal organs) (28, 29). 
1.2.2.5. Molecular Amplification Techniques 
 Molecular methods are relatively newly introduced methods and developed as result of 
advancement in technology. These tests are developed to detect genetic material (DNA & 
RNA) specific to Mtb directly from the clinical samples using amplification techniques. 
Polymerase chain reaction (PCR) is one kind of amplification techniques. Some of these tests 
have been developed in-house and some are commercially available on the market. Each one 
of them uses different method to amplify specific nucleic acid regions of Mtb. However, it is 
only a few tests which are approved by the Food and Drug Administration (FDA). These are 
Amplified MTB Direct Test (AMTD), Amplicor™ tests to test for smear positive respiratory 
samples, and second generation AMTD (E-AMTD) for smear-negative samples (30,31). 
Regarding sensitivity and specificity, there are differences among the different types of tests. 
In one review, the sensitivity and specificity among smear positives was 85% and 97% 
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respectively, whereas among smear negative, it was 66% and 98% respectively. The 
limitations of these diagnostic methods are that they are expensive; require taking specimen 
from the diseased organ and demand qualified personnel. (32, 33)   
1.2.2.6. Immuno.diagnostic Tests 
Immune based tests assess either the immune response of the host against Mtb or detect the 
presence of Mtb antigens. The human response to infection with Mtb involves both humoral 
and cell mediated immunity. As result of advancement in the knowledge of TB immunology 
substantial resources are currently being spent on the development of news tests (33). 
Detection of specific antibodies in sera of suspected patients, usually using enzyme-linked 
immunosorbent assay (ELISA) is one of the most common immune-based diagnostic tests 
(20). It is generally agreed that detection of antibodies is simple, rapid, and relatively less 
expensive, and does not require specimen from the organ affected (34). Several antigens have 
been identified and evaluated for their diagnostic potentials in TB. Some of the antigens are 
evaluated in-house (not yet commercialized) and some are commercialized and are already on 
the market. However several studies done on  the diagnosis of TB using commercial tests 
showed big variation of sensitivity and specificity (35, 36, 37, 38, 39, 40, 41).  Because of this 
sensitivity and specificity problem, the WHO strongly recommends that commercial 
serological tests should not be used for the diagnosis of TB (42). 
1.2.4.7. Interferon Gamma Release Assays (IGRAs) 
IGRAs are recently introduced tests with an increasing evidence of higher specificity than 
TST (43). Like TST, they do not detect the actual TB bacilli but instead they assess and 
measure cellular production of interferon gamma (IFN-) in response to Mtb specific antigens, 
early secretory antigenic target (ESAT-6) and culture filtrate protein (CFP-10). These 
antigens are encoded by the region of difference 1 (RD1), a chromosomal region preserved in 
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virulent strains of MTC, but deleted from BCG and most non-tuberculosis mycobacteria 
(NTM). Thus, IGRAs have no cross reactivity with BCG vaccination and NTM infection 
which reduces false positive results.. The most common IGRAs that have been approved by 
the U.S. Food and Drug Administration (FDA) are QuantiFERON®-TB Gold In-Tube test 
(QFT-GIT) and T-Spot®.TB test (T-Spot). They are primarily designed to detect latent TB, 
but also aid for the diagnosis of active TB. IGRAs require a single patient visit and results can 
be available within 24-48 hours.   However, problems with these tests are high cost; lack of 
gold standard and their failure to differentiate active TB disease from latent TB infection that 
subsequently limit their role in high TB burdened areas (23).  There is also low quality 
evidence and insufficient data on the performance of IGRAs in low- and middle-income 
countries, especially with a high TB and/or HIV burden. As with TST, IGRAs cannot 
accurately predict the risk of infected individuals developing active TB disease and appear to 
have only modest predictive value, suboptimal sensitivity, and do not help in identifying those 
who are at highest risk of progression to disease (44).  IGRAs have shown comparable results 
with TST in screening health care workers, household contacts, outbreak investigations, 
children and HIV-infected individuals.  However, some studies have shown wide discordance 
between TST and IGRA results, mostly of the TST-positive/IGRA-negative type (44).  
1.2.4.8. Tuberculin Skin Tests (TST) 
The first tuberculin test was discovered in 1890 by Robert Koch. He prepared an extract from 
a heat-sterilized culture of Mtb and the product was known as an old tuberculin. It was 
initially to be used as a therapeutic agent though the trial failed. But later in time (1907), its 
diagnostic value was subsequently recognized by Clemens Von Pirquet. However, 
subcutaneous test was being used initially, which was later replaced by intradermal technique 
which is known as Montoux test (45). 
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In 1934, Seibert extracted a purified protein derivative (PPD) from autoclaved mycobacteria 
grown on artificial media. TST using PPD proved to be more reproducible and specific.  
Through time and with repeated standardization, PPD has become the international standard 
for all tuberculin (46, 47). So far, various strengths of tuberculin test materials, from 1 to 
250TU (tuberculin unit), have been evaluated. In general, smaller doses of tuberculin test 
materials results in lower sensitivity, and a larger doses results in lower specificity (48, 49). A 
positive reaction to 5TU of PPD standard (PPD-S) was found to have best correlation with the 
degree of contact with TB and the risk of developing TB.  5TU dose of PPD-S is 
recommended by American Thoracic Society (ATS) as a standard regimen for TST (50). 
PPD-RT23 is another widely used tuberculin test material, developed by Staten’s Serum 
Institute of Copenhagen in 1957. Approximately 2TU of PPD-RT23 are accepted as a bio-
equivalent to 5TU of PPD-S by WHO and International Union against Tuberculosis and Lung 
Disease (IUATLD) (51). 
Generally TST are more than100 years old, and they measure cellular immune responses 
against exposure to mycobacteria infections. The reaction to intradermally injected tuberculin 
is a classic example of delayed hypersensitivity reaction to tuberculoproteins. Following the 
injection of tuberculin, the reaction usually begins 5 to 6 hours later, but maximal indurations 
takes place at 48 to 72 hours, and subsides over a period of days (52).   
There are a number of determinants that can affect TST reactivity. Previous BCG vaccination 
can give positive TST results, but this depends on the age at BCG vaccination is given and the 
time interval before skin testing (53). Tuberculin reactivity caused by BCG immunization 
usually wanes over time and is unlikely to persist for more than 10 years after vaccination in 
the absence of Mtb infection. This has been witnessed with a study done in Gambia among 
infants with BCG vaccination and non-BCG vaccinated (54). Another factor that can affect 
TST is immune status of the individuals that undergo the test. It is generally understood that 
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individuals with suppressed immune status have lower TST response or might not respond to 
the test. Factors that are usually associated with suppressed immune status are among other 
things HIV/AIDS, diabetes mellitus, cancer diseases, protein energy malnutrition and taking 
steroid drugs for longer period. However the absence of a reaction to a TST because of a 
weakened immune system (anergy) does not exclude a diagnosis of TB disease or infection 
with Mtb (55,56).   Hence, it is very important to pay attention to the above factors when 
interpreting the results of TST. 
Interpretation of the test result is based on risk categories (52). Therefore, it is important to 
consider the overall clinical situation of the individual under study. Different cut off values 
have been recommended for defining a positive TST with different clinical situations. For 
example, people at higher risk for developing TB  (e.g. young children, people with 
HIV/AIDS, immunosuppressive therapy and etc  ...) have a lower cut-off value (≥5mm) .A 
cut-off value ≥10mm would otherwise remain a useful criterion for TST positivity. Higher 
cut-off values (≥15mm) show higher chance of TB infection, but this is not always true (44, 
45, 57, 58). For example,  a study on utility of size of tuberculin reactions for the diagnosis of 
mycobacterial disease have shown that a larger induration does not simply imply  a higher 
chance of concurrent TB reactivity (59).  
However, TST is not specific for Mtb infection because of the problem of cross reactivity 
with BCG and infection with environmental mycobacterial infections which could also give 
positive results. Studies have shown that larger indurations occur as a result of Mtb infection, 
not due to BCG vaccination (60), but according to study done in Sweden on BCG vaccinated 
health workers, they have found larger indurations. 
Despite its limitations, TST has been widely used as a screening test in many countries and 
has contributed substantially to generate valuable epidemiological information on infection 
trends and on the magnitude of the disease. Many countries, especially western countries are 
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still using TST for screening of latent TB among targeted groups. Migrant people from the 
high TB endemic countries are usually their main focus (44, 61, 62).   Moreover, TST is a 
valuable tool for the screening of household contacts and suspected cases of TB in BCG 
vaccinated subjects and in population with high BCG vaccination coverage (63).   Studies 
have also shown that the role of TST for screening of TB infection and diagnosis of latent TB 
is almost similar with that of IGRAs in high TB burden countries (64). 
According to the traditional cut-off points of PPD set by WHO and Centers for disease control 
(CDC), a reaction of ≥ 10 mm of induration should be considered positive for those persons 
with an increased probability of recent infection or with other clinical conditions that increase 
the risk of TB (e.g. recent immigrants from high prevalence countries and injection drug 
users) (65).Western countries such as Norway and USA screen routinely migrants from high 
TB endemic countries like Ethiopia upon arrival, and use the traditional cut-off points of PPD 
in the diagnosis of TB. However, in a recent study conducted in Ethiopia a large number of 
individuals who had skin indurations <10mm were found positive for latent TB infection by 
QFT-GIT (66). Another study also indicated the importance of modifying of the traditional 
cut-off points of TST for TB diagnostic purpose (67).  In addition, based on my personal 
communication with |health personnel at Ullevaal hospital in Norway who are engaged in 
screening immigrants for TB using TST, most immigrants, including those from Ethiopia 
have skin induration of ≥10mm, but the number of immigrants who develop clinical TB are 
very few. Therefore, considering the effect of environmental mycobacterium and BCG 
vaccination in most developing countries, including Ethiopia , the cut-off point recommended 
by WHO for screening of TB infection require re-assessment. In high TB burden countries 
including Ethiopia, it is believed that around 90% of the population is already exposed to TB. 
With these ideas in mind, this study was designed to compare the size of skin test induration 
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in smear and culture positive TB patients, their household contacts and community controls to 
optimize the cut-off points for the diagnosis of TB in Ethiopia 
1.3. Research Hypothesis and Objectives 
1.3.1. Research Hypothesis 
The cut-off point of TST recommended by WHO and CDC may not discriminate between 
clinical TB and infection, and infection from exposure to environmental mycobacteria in high 
TB endemic countries such as Ethiopia 
1.3.2. General Objectives 
To evaluate and optimize the cut-off point of TST for the diagnosis of TB in Ethiopia or 
migrants from Ethiopia.  
 1.3.3. Specific Objectives 
1. To measure and compare mean values of skin test induration in TB patients, their 
contacts and community controls  
2. To compare mean values of skin test induration among BCG vaccinated and non BCG 
vaccinated study participants  
3. To compare the diagnostic performance of TST and QFT-GIT in TB patients, their 
contacts and community controls 
4. To suggest the optimum cut-off values in clinical TB, Mtb infection and absence of 
Mtb infection   
 
 
 
29 
 
Chapter 2: Methodology 
2.1. Study Area 
The study was conducted in Addis Ababa, The capital city of Ethiopia.  Addis Ababa is also 
the seat for African Union (AU). The city is divided into10 zones with an estimated 
population of 3.5 million according to population census of 2007 (66). Geographically, it lies 
at 2300meters above sea level and has a subtropical highland climate. The high elevation 
moderates the temperatures year- round, and the city’s position near the equator means that 
temperatures are very constant from month to month.   
The people of Addis Ababa are engaged in different activities among others trade and 
commerce, manufacturing and industry, civil administration, homemakers of different 
varieties, transport and communication, education, health, social services, and hotel and 
catering services. According to the 2007 population census, 98.64% of the population had 
access to safe drinking water; 85.7% had access toilet facilities. Adult literacy was 93.6% for 
men and 79.95% for women (67). 
Regarding the overall development within the region, it is relatively better developed 
compared to the rest of the country. Services such as access to drinking safe water, access to 
health care services, transport, electricity and telephone do not still fit people’s demand. 
HIV/AIDS and TB are among the major public health problems of the inhabitants of Addis 
Ababa (68).  Based  on the information obtained from hospitals and regional health office in 
Addis Ababa, hospitals offer treatment and follow up for multidrug resistant TB as well as for 
TB/HIV co-infections whereas the rest of TB types will be referred to the nearby health 
centers where  anti-TB treatment is offered. Based on health related information obtained, six 
health centers were purposefully selected, including  Kolfe, Yeka, Meshowalkia, Nifas-Silk, 
Saris and Kality health centres. 
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2.2. Study Design 
A quantitative, cross-sectional study design was used, in which PTB suspects coming to the 
selected health facilities were recruited consecutively, clinically examined and biological 
samples were collected. The status of clinical TB or smear positive PTB was confirmed using 
sputum microscopy, chest X-ray and culture. Household contacts of PTB patients and 
community controls were screened for TB infection using questionnaires, TST, QFT-GIT and 
chest x-ray.  In this study, we were interested to see whether there was a significant difference 
in the mean size of TST among the different subgroups of the study participants (PTB patients 
and their contacts as well as community controls). Community controls were recruited 
randomly from the same population and subsequently they were also screened for TB 
infection using questionnaires, TST, QFTGIT assay, and with chest X-ray depending on the 
size of skin induration.   To avoid or minimize biases in this study, TB index cases were 
recruited consecutively; household contacts traced using the index cases and recruitment of 
community controls done randomly from population living in the neighborhood.  Data such as 
clinical status, QFT-GIT assay, sputum samples, and anthropometric measurements were 
collected. Provider initiated HIV counseling and testing was done for all voluntarily to 
participate in the study and only those who were negative were included in the study. To 
compare values of TST among BCG vaccinated and non BCG vaccinated study participants 
the presence of BCG scar was considered as the main criteria for deciding the vaccination 
status.  
2.3. Study Population 
Management of TB in Ethiopia is almost based on passive case detection in which patients 
visit health facilities by their own initiatives when they get ill and subsequently get treatment. 
All PTB suspects who came to the selected health facilities were part of our study population. 
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Household contacts of TB index cases and   community controls from the same area were also 
part of study population. 
2.4. Selection and Recruitment of Participants 
Study participants were selected from the study population according to the following 
inclusion and exclusion criteria. 
2.4.1. Inclusion Criteria 
Participants fulfilling all the following criteria were included in the study.  
1. Newly diagnosed smear positive PTB (diagnosed based on smear microscopy and later 
confirmed with culture). These are TB index cases 
2. Household contacts (persons who share the same house)  of  TB index cases 
3. Participants who  voluntarily agreed to participate in the study 
4. Community controls from the same area with TB index cases and household contacts 
that were willing to participate in the study 
5. Age above 15 years old 
2.4.2. ExclusionCriteria 
1. Smear negative and extra PTB patients  
2. Previous history of TB for community controls  
3. Children below 15 years old  
4. People who are not volunteer to participate 
5. Pregnant women and  seriously sick patients 
6. individuals who have a problem of drug allergy 
7. HIV infected individuals 
8. People who are on immunosuppressive drugs 
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9. People who have chronic medical illness such as diabetes, cancer and etc. 
2.5. Sample Size and Sampling Method  
In order to measure and compare the mean values of TST in smear positive PTB patients, 
their contacts and community controls   it was estimated to recruit a total number of 78 
eligible smear positive PTB patients, 78 close contacts and 78 community controls by 
assuming a mean diameter induration and standard deviation of 16.8 ± 3.8 mm among smear 
positive TB patients (Cobelens et al., 2006) and  a mean diameter induration  and  standard 
deviation of 13.0 ± 11.29  mm  among  smear-positive TB patients’ contacts (Lao and De 
Guia, 1999), while assuming  a power of 80% and  95% confidence interval.   
 The formula, n≥ (1.96)2[p (1-p]/ (CI) 2, for the evaluation of diagnostic tests for infectious 
diseases was used to estimate the required sample size (60 smear-positive TB cases, 60 
household contacts and 60 community controls) for the fourth specific objective (69). Then, 
people who met the inclusion criteria and who volunteered to participate in the study were 
recruited until the required number of participants is obtained 
2.6. Sample Collection and Tests 
2.6.1. Sputum Collection and Smear Preparation 
Collection of sputum was done following standard procedures (spot-morning-spot). Study 
participants were instructed how to produce quality sputum (mucoid and mucopurulent) and 
adequate sputum (3-5ml).Sterile sputum cups, approximately 10ml, were used for sputum 
collection. Sputum cups were labeled properly with a unique identification number which 
corresponds to every participant with sputum.  Smear preparation, staining using the Ziehl-
Neelsen (ZN) stain and examination for AFB were done according to WHO guideline (68) at 
the respective health facility by an experienced laboratory technician. A minimum of 100 oil 
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immersion fields were examined before a negative result was declared. Positivity was 
confirmed when at least two out of the three smear results were positive for AFB (70). 
2.6.2. Culture 
A portion of the sputum sample was transported to Aklilu Lemma Institute of Pathobiology 
laboratory under cold condition and processed for culture after the samples were 
homogenized and decontaminated. Decontamination process was done using modified Petroff 
methods (71). For decontamination of the sputum samples, 4% sodium hydroxide (4%NaOH) 
was used. The mixture was centrifuged and subsequently, the sediment was separated from 
the supernatant and 0.2-0.4ml of this centrifuged sediment was inoculated and distributed on 
conventional solid media culture (Lowenstein-Jensen (LJ)) and incubated for up to eight 
weeks at 37°C.  Inspection of culture was done on the seventh day after inoculation to look 
for the growth of rapidly growing Mycobacterium to differentiate them from MTC.  
Inspection was intended to be done after 4 weeks of inoculation to look for the growth of Mtb 
or other slow growing bacterial contaminants and positivity for AFB was confirmed by 
microscopy. 
2.6.3. QuantiFERON®-TB Gold In-Tube (QFTGIT) Assay 
QFT-GIT assay was performed according to the manufacturer’s instructions 
(QuantiFERON®-TB Gold In-Tube, Cellestis Ltd., Carnegie, Australia). Briefly, a venous 
blood sample (1ml) was collected from each individual into three tubes (one containing TB-
specific antigens, one containing mitogen and a nil tube). The samples were transported to 
Armuer Hansen Research Institute (AHRI) within 4-6 h of collection and incubated for 24 h at 
37 
0
C. Then, samples were centrifuged at 3000 x rcf (relative centrifugal force) for 15 min, 
and the plasma was collected and stored at -80
o
C until the IFN- assay was performed using 
ELISA kits. The optical density (OD) of each test was read using a 450 nanometres filter with 
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a 620 nm reference filter, using an ELISA plate reader. The results were interpreted as 
positive, negative or indeterminate on the basis of the manufacturer’s recommended cut-off 
value (IFN-γ  0.35 IU/ml) using QFTGIT analysis software developed by the company. 
2.6.4. Administration and Reading of TST 
WHO guideline and international standard were followed in inoculation of PPD and 
measuring of indurations. The Mantoux method of intradermal injection was used for 
tuberculin PPD administration.  In this method, 0.1ml tuberculin test material that contains 2 
TU PPD (Tuberculin PPD RT23)   was injected intradermally into the volar aspect of the 
forearm according to the instruction of the manufacturer (Statens Serum Institute, 
Copenhagen, Denmark). The chosen skin area was checked for free of lesions and veins and 
the injection was made using a disposable tuberculin syringe, which was a 1 ml syringe 
graduated in hundredths of milliliters. The tuberculin was injected just beneath the epidermis 
with the needle bevel upward at an angle to the forearm by well experienced nurse.  A 
discrete, pale wheal with a diameter of 6-10 mm has been produced after the proper injection 
of PPD (figure 2a). In a very few of the participants an immediate repeat of PPD 
administration has been done at a distance of two inches from the first site of PPD injection 
since there was failure to produce bump with the first administration. An opposite arm was 
used in one participant since the participant had a big scar on the first forearm. The TST result 
was read at 72 hours after injection in all participants. After the correct induration was 
produced, the largest transverse diameter, measured in millimeters perpendicular to the long 
axis of the forearm was taken (Figure 2b). Subsequently, results have been interpreted as 
positives/ negatives based on the size of the induration measured.  Results of ‘0 mm’ were 
recorded as zero instead of ‘negative’ in the absence of an induration. 
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Figure 2a: Bump created right after PPD injection 
 
Figure 2b: Skin test induration at 72 hours of PPD injection 
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2.6.5. Chest X- ray 
 Chest x-ray was taken from participants (household contacts and community controls) with 
TST results ≥10 mm as a supplementary test for the diagnosis of LTBI or active TB. The 
results of the chest x-rays were interpreted by an expert /radiologist. 
2.6.6. Anthropometric Measurements 
Weight in kilograms and height in centimeters of each study participants were taken using a 
weight scale fixed to an upright height scale. Hence, body mass index (BMI) was calculated 
for each participant using the formula, weight in kilograms divided by the square of height in 
meters (kg/m
2
).
  
The results were interpreted using the international classification of adult 
BMI (BMI<18.50=underweight, BMI 18.50-24.99= normal, BMI 25-29.99= overweight, and 
BMI≥30= obese) (72).   
2.7. Data Collection Forms 
A questionnaire was used to gather data (socio-demographic and clinical data) about all 
participants (see appendices). 
2.8. Data Management and Analysis  
All information about the participants has been kept confidentially. Data quality was assured 
through introducing of pretesting of questionnaires and use of /trained   nurses for data 
collection. Standard procedures were used for sample collection, storage and laboratory 
works. Quality control was used during running of laboratory tests. All participants were 
given unique identity number instead of their names and subsequently data was entered first 
into epidata version 3.1 and then it was exported into SPSS for windows version 16 for further 
analysis. Socio-demographic characteristics and prevalence of Mtb infection as diagnosed 
using TST and QFTGIT were summarized using simple descriptive statistics (frequencies and 
percentages).Mean is presented for normally distributed variables, and median for non-
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normally distributed variables. Agreement between TST and QFTGIT was assessed using 
Cohen’s Kappa (K) coefficient. A k-value of 1 implies perfect agreement whereas k-value < 1 
simply means less than perfect agreement (73).  Different people have different interpretations 
as to what is a good level of agreement. Here is one possible interpretation of kappa (73): 
poor agreement (k <0.2), fair agreement (k= 0.2-0.4), moderate agreement (k= 0.4-0.6), good 
agreement (k= 0.6-0.8) and very good agreement (k= 0.8-1). P-values, odd ratios and 95% 
confidence intervals are provided to see the possible association of participants’ background 
characteristics (e.g. age, sex, BCG scar, BMI and so on) with TST and QFTGIT positivity. 
The same statistics were used to evaluate the discordance between the two tests. Two-sample 
t-test with equal variance analysis was used to compare quantitative variables; here it was 
used to compare the mean values of skin test induration and levels of interferon gamma 
among subgroups of study participants. The chi-square test was used to compare categorical 
variables. A p-value <0.05 was considered statistically significant for each statistical test 
performed.  Sensitivity and specificity as well as cut-off points of TST for each subgroup 
were calculated using receiver operating characteristic (ROC) curve. Data were analyzed 
using SPSS for windows version 16. 
2.9. Ethical Consideration 
This project has been ethically approved by the Norwegian Ethical Committee (REK, Sør-
Øst) the Institutional Review Board (IRB) of the Aklilu Lemma Institute of Pathobiology, and 
the National Research Ethics Review Committee of Ethiopian Science and Technology 
Ministry. Participants of this study were informed about the purpose of the study as well as 
risks and benefits associated with it before they gave their consent. They were granted their 
freedom to withdraw from their participation at any time during the study and also assured 
that their decision to decline from the study has no impact on their routine health care they 
would be offered.  Care has been taken during tuberculin PPD injection and blood collection 
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to avoid or minimize pain and risk of infection. Participants were also informed that if they 
encounter health problem as a result of the procedure, he/she would be offered medical help. 
Individuals who had sign/symptoms of active TB and those who have PPD≥10 mm  have 
undergone further investigation for TB so that they could get appropriate treatment. In the 
case of children under 18, but older than 15 years of age assent was obtained from each child 
in addition to the consent obtained from their parents. 
All participants were offered provider initiated HIV counseling and testing. Both counseling 
and testing was done confidentially without any problem. There was a fear that many could 
refuse testing but surprisingly almost all of them accepted the test. Since the majority of the 
participants were literate, understanding each other and obtaining their consent hasn’t been a 
problem during this study.  
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Chapter 3: Results 
3.1. Socio-Demographic and Baseline Characteristics of Study Participants 
Initially, 250 individuals (123 males and 127 females) were invited to participate in this study. 
Of these, 26 (13 males and 13 females) were excluded because of pre-specified exclusion 
criteria such as HIV, Diabetes, pregnancy, and previous history of TB.  Although one male 
and one female died during the study period after data was gathered, their data are included in 
the analysis. Two participants from household contacts were diagnosed as having TB during 
the study period and they started on anti-TB treatment. Overall a total of 224 (50 PTB 
patients, 96 household contacts and 78 community controls) participants were included in the 
final analysis.  
Socio-demographic characteristics of the study participants are summarized in table 2. The 
mean age is 31.1 years for PTB Patients, 32.4 years for household contacts, and 32.6 years for 
community controls whereas the median ages for the respective subgroups are 24.5 years, 28 
years and 30 years. The number of male participants is slightly larger in PTB patients (58%) 
and in household contacts (52.08%) whereas in community controls the proportion of females 
(60%) was higher.  The majority of the study participants were Christians (88.4%) and literate 
(85%).  Approximately 80% of the participants were engaged in some kinds of activities to 
manage themselves economically.  
The baseline characteristics like BCG status, nutritional status, smoking and alcohol 
consumption of the participants are summarized in Table 2.  BCG scar was observed in 12 (24 
%) PTB patients, 44 (45.8%) household contacts and 33 (42.3%) community controls.  
Approximately 25(50%) of the patients, 18 (18.8%) of the household contacts and 5(6.4%) of 
the community controls were underweight (BMI <18.5 kg/m2). Some of the study participants 
reported use of substances (cigarette, khat and alcohol) (Table 3). 
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Table2. Socio demographic characteristics of study participants 
Characteristics Patients(n=50) Contacts(n=96) Controls(n=78) 
Age 
15-30 
31-45 
>45 
Sex  
 Male 
Female 
Marital status 
Single 
Married 
Divorced 
Partnership 
Widow 
Religion 
Orthodox 
Catholic 
Protestant 
Muslim 
Others 
 
37(74 %) 
5(10 %) 
8((16 %) 
 
29(58 %) 
21(42 %) 
 
30(60 %) 
17(34 %) 
3(6 %) 
0(0 %) 
0(0 %) 
 
37(74 %) 
1(2.0 %) 
4(8.0 %) 
0(0, 0 %) 
8(16.0 %) 
 
59(61.5 %) 
21(21.9 %) 
16(16.7 %) 
 
50(52.1 %) 
46(47.9 %) 
 
43(45.3 %) 
43(45.3 %) 
1(1 %) 
3(3.2 %) 
5(5.2 %) 
 
75(78:1 %) 
2(2.1 %) 
5(5.2 %) 
11(11.5 %) 
3(3.1 %) 
 
40(51.3 %) 
25(32.1 %) 
13(16.7 %) 
 
31(39.7 %) 
47(60.3 %) 
 
35(44.9 %) 
26(33.3 %) 
9(11.5 %) 
1(1.3 %) 
7(9 %) 
 
66 (84.6 %) 
0 
8(10.3 %) 
4(5.1 %) 
0 
Ethnicity 
Amahara 
Oromo 
Tigre 
Gurage 
Others 
Level of Education 
Can’t read and write 
Can read and write 
Primary school 
Secondary school 
Higher education 
Occupation 
Trader 
Employee Unemployed 
Student 
House wife 
Others 
 
23(46 %) 
10(20 %) 
3(6 %) 
6(12 %) 
8(16 %) 
 
7(14 %) 
6(12 %) 
9(18 %) 
26(52 %) 
2(2 %) 
 
5(10 %) 
15(30 %) 
7(14 %) 
6(12 %) 
9(18 %) 
8(16 %) 
 
36(37.5 %) 
28(29.2 %) 
10(10.4 %) 
18(18.7 %) 
4(4.2 %) 
 
11(11.5 %) 
7(7.3 %) 
26(27.1 %) 
35(36.5 %) 
17(17.7 %) 
 
11(11.5 %) 
32(33.3 %) 
16(16.7 %) 
11(11.5 %) 
18(18.8 %) 
8(8.3 %) 
 
49(62.8 %) 
18(23.1 %) 
2(2.6 %) 
6(7.7 %) 
3(3.8 %) 
 
15(19.2 %) 
6(7.7 %) 
17(21.8 %) 
36(46.2 %) 
4(5.1 %) 
 
3(3.8 %) 
9(11.5 %) 
16(20.7%) 
13(16.7 %) 
20(25.6 %) 
17(21.8 %) 
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Table 3: Baseline characteristics of the study participants  
Baseline 
characteristics  
Patients  
No (%) 
Contacts  
No (%) 
Controls  
No (%) 
Total  
BCG scar  
Yes  
No  
Indeterminate  
 
12 (24 %)   
33(66 %)      
5(10 %)           
 
44(45.8 %)   
39(40.3 %)    
13(13.5 %)       
 
33(42.3 %) 
41(52.6 %)   
4(5.1 %)          
 
89(39.7 %) 
113(50.5 %)  
22(9.8 %)       
BMI in Kg/m2 
<18.5   
18.5 -24.99 
>= 25 
 
25(50 %) 
24(48 %)         
1 (2 %)   
 
18(18.8 %)       
71(74.0 %)   
7(7.3%) 
 
5(6.4 %) 
53(68.0 %)        
20(25.6 %)  
 
48 (21.4%) 
148((66.1%) 
28(12.5%) 
Alcohol consumption  
Yes  
No 
 
13 (30.2%)         
30 (69.8%) 
 
32 (37.6%) 
53(62.4%) 
 
27 (35.1%) 
50 (64.9%) 
 
72(35.1%) 
133 (64.9%) 
Smoking  
Yes  
No 
 
8 (18.6%)         
35 (81.4%) 
 
12 (14.1%)       
73(85.9%) 
 
4 (5.2%)          
73 (94.8%) 
 
24 (11.7%) 
181 (88.3%) 
Chewing khat 
Yes  
No 
 
10 (23.3%)       
 33 (76.7%) 
 
12 (14.1%)        
73(85.9%) 
 
10(13%)           
67 (87%) 
 
32 (15.8%) 
171(84.2%) 
 
3.2. AFB and culture 
Sputum was collected from 53 of the study participants (48 PTB suspects and 5 household 
contacts), and smear microscopy was done at health facilities and  all of PTB suspects were 
positive for AFB and 2 of the 5 the household contacts turned also positive for AFB. AFB for 
the first 40 PTB suspects was also done at ALIPB and all turned positive.   Similarly, culture 
was done for these 40 PTB suspects. At the end of the first month of culturing, 29 individuals 
turned positive for culture. The plan was to follow until 8weeks to see the result of the 
remaining 11 individuals and also to do AFB for the remaining 8 individuals at ALIPB. 
However, due to the collapse of the laboratory building the plan could not be realized.  
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3.3. Major Symptoms Reported by Participants 
All participants were assessed for clinical symptoms suggestive of TB using questionnaires, 
and the majority of PTB diagnosed patients had major symptoms of TB, whereas only few 
from the household contacts had some symptoms suggestive of PTB (Table 4).  Two 
participants from the household contacts were found to have PTB after they had undergone all 
the tests related to this study. All of them have been put on anti-TB treatment according to 
WHO guideline for the treatment PTB at the respective health center.  
Table 4: Major symptoms reported by participants 
Symptoms TB Patients Contacts Controls 
Cough >2weeks 48 (96%) 16(16.7%) 2(2.6%) 
Fever 39 (78%) 5(5.2%) 2(2.6%) 
Sweating 37(74%) 11(11.46%) 1(1.3%) 
Loss of appetite 43(77%) 6(6.25%) 2 (2.6%) 
Shortness of breath 38(76%) 11(11.5%) 1(1.3%) 
Weight loss  41(82%) 8 (8.3%) 3(3.8%) 
Chest pain 41 (82%) 9 (9.4%) 4 (5.1%) 
Weakness 45(90%) 12 (12.6%) 4(5.1%) 
Other problems 5 (10%) 3 (3.2%) 0(0%) 
3.4. Prevalence of Mtb Infection 
Table 5 shows the prevalence of Mtb infection by TST and QFTGIT. TST was done  for 
211(106 males and 105 females) of the study participants,  At the cut-off point of TST 
≥10mm, the prevalence of  Mtb infection  among household contacts was 72.2% , while it was 
46.7% among  community controls .  Interestingly, all PTB patients had skin test induration 
>10mm. However, some household contacts 12 (13.6%) and relatively high number of 
community controls 33 (44%) had no induration, meaning they had 0 mm of skin induration. 
The percentage of TST distribution for each subgroup is represented by figures 1a-c. 
 The proportion of TST positivity   did not differ between males and females in household 
contacts (78.3% vs. 66.7%, x2 = 1.4879, p= 0.223). However, it was significantly higher in 
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males compared to females in the community controls (61.3% vs. 36.4%, x
2
 = 4.5402, p= 
0.033).  The proportion of TST positivity did not significantly differ by age categories both in 
contacts (x
2
= 0.5246, p= 0.769) and controls (x
2
= 5.6767, p=0.059).  On the other hand, the 
proportion of TST positivity was significantly higher in individuals who had BCG scar 
compared to individuals who had no BCG scar, or indeterminate cases (89.7% vs. 50.0%, x
2
 = 
15.9947, p<0.001).The proportion of TST positivity did not significantly differ by nutritional 
status of the study participants and use of substances (cigarette, khat and alcohol) both in 
contacts and community controls.   
The mean size of TST induration was significantly higher in PTB patients (18.1mm) 
compared to that of household contacts (13.6 mm) and community controls (7.9 mm). The 
mean values of TST in PTB patients and household contacts were compared and the 
difference was found to be significant statistically (p=0.0002).  Similarly, there was a 
significant difference between the mean values of TST in household contacts and community 
controls (p< 0.001).   There was no significance difference between the mean of skin test 
induration size of males and females in PTB patients (17.9 mm vs. 18.4 mm p= 0.6527) and 
in contacts (14.1 mm vs. 13.0 mm, p= 0.5007). However, the mean size of skin test induration 
in males was higher than that of females in community controls (10.5 mm vs. 6.0 mm, p= 
0.0146).  The mean size of skin test induration did not differ by age categories (p> 0. 05). The 
mean size of skin test induration size was higher in individuals who had BMI value > 18.5 
kg/m2 compared to individuals who had BMI < 18.5 kg/m2 in PTB patients (19.1mm vs. 
17.1mm, p= 0.0276). The mean size of skin test induration did not differ in contacts and 
community controls by BMI status of the individuals (p> 0.05).  The mean size of skin test 
induration was higher in individuals who had BCG scar compared to individuals without 
BCG scar in household contacts (F= 6.8, p=0.0018). Considering all participants as whole, the 
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mean difference of TST in BCG vaccinated and non-BCG vaccinated participants was 
statistically significant (p = 0.0136). 
Figure 3a. Tuberculin skin test distribution in PTB patients 
 
Figure3b.  Tuberculin skin test distribution in household contacts 
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Figure 3c.  Tuberculin skin test distribution in community controls 
 
Similarly, QFTGIT was done for 193 (86.2%) of the study participants (44 PTB patients, 91 
household contacts and 58 community controls). At the cut-off point   ≥0.35 IU/ml of  IFN- , 
the prevalence of Mtb  infection  was found to be  81.8%,  70.3%  and  55.2%  among   PTB 
patients,  household contacts and  community controls , respectively. 
The mean level of IFN-   was 4.68 IU/ml in PTB patients, 4.90 IU/ml in contacts and 2.62 
IU/ml in community controls. There was no significant difference between the mean level of 
IFN-  in PTB patients and household contacts (p= 0.8095). However, there was a significant 
difference between the mean level of IFN-  in PTB patients and community controls as well 
as   in household contacts and community controls (p< 0.05).  The mean level of IFN- and 
proportion of QFTGIT positivity   did not differ by gender, age categories, BCG scar, BMI 
status, or use of substances (cigarette, khat and alcohol) in PTB patients, in contacts and in 
community controls (p> 0.05). 
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Table 5. Prevalence of Mtb infection by TST and QFTGIT test in the study participants 
 
 
 
 
 
The mean IFN-  level was significantly higher in individuals who had skin test induration 
greater than 10 mm compared to those individuals who had skin test induration of ≤10mm in 
all the study groups and among the subgroups (Figure 2a-d). 
Figure 4a.  The mean IFN-  level in all study participants in relation to skin test induration  
 
 
 
 
 
Test and cut-off 
point 
Patients Contacts Controls Total                   
TST in mm 
<10mm 
≥10 and<15mm 
≥15mm 
 
0 
11(23%) 
37(77%) 
 
24(27.3%) 
24(27.3%) 
40(45.4%) 
 
40(53.3%) 
19(25.5%) 
16(21.5%) 
 
64(30.3%) 
54(25.6%) 
93(44.1%) 
IFN- level (IU/ml) 
≥ 0.35 IU/ml 
< 0.35 IU/ml 
 
36 (82%) 
8 (18%) 
 
64 (70.3%) 
27(29.7%) 
 
32(55.2%) 
26(44.8%) 
 
132(68.4%) 
61(31.6%) 
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Figure 4b.  The mean IFN-  level in patients in relation to skin test induration  
 
Figure4c.  The mean IFN-  level in contacts in relation to skin test induration 
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Figure 4d.  The mean IFN-  level in community controls in relation to skin test induration  
 
In patients, it was found that there was poor correlation between the size of skin test 
induration and the level of IFN-  (Spearman’s rho= 0.1665, p= 0.2800), whereas there was 
positive correlation between the size of skin test induration and the level of IFN- (induced 
against the specific antigens) in household contacts (Spearman’s rho= 0.3916, p= 0.0002) and 
community controls (Spearman’s rho= 0.6552, p< 0.001) (fig 3a-d).  On the other hand, there 
was no correlation between PHA induced IFN- and skin test induration in all the subgroups.   
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Figure 5a.  Correlation between the level of IFN-  and the size of skin test induration in all 
participants  
 
 
Figure 5b. Correlation between the level of IFN-  and the size of skin test induration in TB 
patients (Spearman’s rho= 0.1665, p= 0.2800) 
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Figure 5c. Correlation between the level of IFN-  and the size of skin test induration in 
contacts (Spearman’s rho= 0.3916, p= 0.0002) 
 
Figure 5d. Correlation between the level of IFN-  and the size of skin test induration in 
community controls (Spearman’s rho= 0.6552, p= 0.0000) 
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3.5. TST and Chest X-ray  
In this study, taking chest X-ray for the study participants with TST ≥10mm was one of the 
requirements in household contacts and community controls. However, chest X-ray was taken 
only from 40 (62.5%) of household contacts with TST results ≥10mm and 20 (57.1%) of 
community controls.  Among household contacts who had chest X-ray, only two participants 
had abnormal chest x-ray which was suggestive of PTB.  None of the community controls 
showed abnormal chest x-ray results.  
3.6. Association of Background Characteristics of Participants with TST 
and QFTGIT Positivity 
Using a logistic regression, the association of background characteristics of study participants 
with TST and QFTGIT positivity has been assessed (Table 5 &6). Being a female was 
significantly associated with low skin test positivity in community controls (crude odds ratio 
= 0.36, 95% CI, 0.14 to 0.93, p= 0.035).  Similarly, age group between 31-45 years was 
significantly associated with TST positivity in community controls (crude odds ratio = 3.33, 
95% CI, 1.15 to 9.65, p= 0.026). Lack of BCG scar was significantly associated with low TST 
positivity in contacts (adjusted odds ratio= 0.09, 95%CI, 0.02 to 0.46, p=0.001,).  TST 
negativity was significantly associated with QFTGIT negativity both in contacts (adjusted 
odds ratio=0.03, 95%CI, 0.01 to 0.15, p <0.001) (Table 5) and in community controls 
(adjusted odds ratio=0.02, 95%CI, 0.00 to 0.12, p <0.001) (Table 6). 
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Table 6a. Association of baseline characteristics of the study participants with TST positivity 
in household contacts 
Baseline characteristics  Contacts  
No. positive (%) 
COR,( 95 % CI) AOR,( 95 % CI) 
Sex  
 Male 
Female 
 
36(78.3%) 
28(66.7 %) 
 
Reference  
0.56(0.21 -1.43) 
 
Reference 
Age 
15-30 
 31-45 
>45 
 
38(70.4 %) 
15(78.9 %) 
11(73.3 %) 
 
Reference  
1.58(0.45-5.50) 
1.16(0.32-4.18) 
 
BCG scar  
Yes  
No  
Indeterminate  
 
35(89.7 %) 
18(50.0 %)    
11(84.6 %)              
  
Reference  
0,11(0,03-0,39) 
0,63(0,10-3.91) 
 
Reference  
0.09(0.02-0.46) 
0.31(0.03-3.12) 
BMI in Kg/m2 
<18.5   
18.5 -24.99 
≥25 
 
14(82.4 %)       
46(69.7 %)   
4(80.0%) 
 
Reference  
0.49(0.13-1.91) 
0.86(0.07-10.67) 
 
Alcohol consumption  
Yes  
No  
 
23 (79.3%)       
34(69.4%) 
 
Reference  
0.59(0.19-1.75) 
 
Smoking  
Yes  
No 
 
10 (90.9%) 
47(70.2%) 
 
Reference  
0.24(0.03-1.96) 
 
Chewing khat 
Yes  
No 
 
9 (81.8%)    
48(71.6%) 
 
Reference  
0.56 (0.11-2.84) 
 
IFN-g level (IU/ml) 
≥ 0.35 
<0.35 
 
55(91.7%) 
8(32.0%) 
 
Reference  
0.04(0.01-0.15) 
 
Reference  
0.03(0.01-0.15) 
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Table 6b.Association of baseline characteristics of the study participants with TST positivity 
in community controls  
Baseline characteristics  Controls   
No.positive (%) 
COR,( 95 % CI) AOR,( 95 % CI) 
Sex  
Male 
Female 
 
19(61.3%) 
16(36.4%) 
 
Reference  
0.36(0.14-0.93) 
 
Reference 
0.22(0.02-2.31) 
Age 
15-30 
31-45 
>45 
 
15(37.5%) 
16 (66.7%) 
4(36.4 %) 
 
Reference  
3.33(1.15-9.65) 
0.95(0,24-3.81) 
 
Reference 
9.04(0.76-107.99) 
1.63(0.08-31.63) 
BCG scar  
Yes  
No  
Indeterminate  
 
20(60.6 %) 
14(36.8 %)   
1(25.0 %)          
 
 Reference  
0.38(0.15-0.99) 
0.22(0.20-2.31) 
 
Reference  
0.23(0.03-1.63) 
Omitted  
BMI in Kg/m2 
<18.5   
18.5 -24.99 
≥ 25 
 
2(40.0 %)   
22(42.3 %)      
11(61.1 %)  
 
Reference  
1.1(0.17-7.15) 
2.36(0.31-17.85) 
 
Alcohol consumption  
Yes  
No  
 
23 (79.3%)     
34 (69.4%) 
 
Reference  
1.22(0.46-3.22) 
 
Smoking  
Yes  
No 
 
4 (100.0%)          
31 (44.3%) 
 
Omitted     
……….. 
 
Chewing khat 
Yes  
No 
 
7 (70.0%)        
28 (43.8%) 
 
Reference  
0.33(0.08-1.41) 
 
IFN-g level (IU/ml) 
≥ 0.35 
<0.35 
 
26(81.3%) 
3(11.5%) 
 
Reference  
0.03(0.01-0.13) 
 
Reference  
0.02(0.00-0.12) 
 
Logistic regression analysis was also performed to see whether the background characteristics 
were associated with positivity of QFTGIT. Apart from TST, none of the background 
characteristics was associated with QFTGIT positivity.  There was strong association of 
QFTGIT positivity with TST ≥ 10mm in contacts (crude odds ratio = 23.38, 95%CI, 6.75 to 
80.99, p<0.001) and in community controls (crude odds ratio = 33.22, 95% CI, 7.45 to 
148.17, p< 0.001). 
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3.7. Agreement between TST and QFTGIT Test Results 
Out of 224 participants, 211 (94.2%) were tested by TST, 193(86.2%) were tested by 
QFTGIT and 187(83.5%) were tested by both tests. At the cut-off point ≥10mm for TST, 136 
(72.73%) study participants were positive by TST and at the cut-off point ≥0.35IU/ml of IFN-
 for QFTGIT, 128 (68.50%) participants were positive by QFTGIT. However, looking at 
only participants that were tested by the two tests, at the same cut-off points for TST and 
QFTGIT, 117 (62.6%) participants tested positive for both tests whereas 40 (21.4%) 
participants were negative for both tests.  There were 19 (10.2%) participants who tested 
positive by TST but negative by QFTGIT, and on the other hand, there were 11 (5.9%) 
participants who tested positive by QFTGIT, but negative by TST (Table 7). 
 The difference in positivity by the two test was analyzed using the Pearson chi-square and it 
was found that there was a higher positivity by TST compared to QFTGIT (x
2
=71.3641   P = 
0.000).  Kappa analysis was done to see the strength of the agreement between the two tests 
and considering all participants, the observed percentage agreement (83.9%) was good with 
kappa =   0.6145. Similarly, the analysis was done in the subgroups and there was good 
agreement between the two tests in both household contacts (84.7%, kappa = 0.6183) and 
community controls (84.5%, kappa =0.6897). Out of 44 individuals who had positive skin 
test, 8 (18.2%) individuals were found to be negative by TB-gold. 
Table 7. Agreement between TST at the cut-off point≥ 10mm of skin induration and QFTGIT 
at the cut-off point ≥0.35IU/ml level of IFN - for all participants as a whole (7a) and 
subgroups, separately (7b,7c,&7d) 
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Table 7a.  Agreement between TST and QGTFIT in all participants 
 
QFTGIT 
                          TST  TOTAL  
≥ 10 mm < 10 mm  
≥ 0.35 IU/ml 117(62.6%)  11 (5.9%)  128 (68.5%) 
<0.35 IU/ml 19 (10.2%)  40 (21.4%)  59 (31.6%)  
TOTAL  136 (72.7%)  51(27.3%)  187 
The observed percentage agreement (p (a)):= 83.96%      k= 0.6145                                          
The probability of random agreement (p (e)) = 58.39%      
Table 7b. Agreement between TST and QGTFIT in patients 
QFTGIT                              TST  
≥10mm <10mm Total 
≥0.35IU/ml 36(81.8 %) 0 36 
<0.35IU/ml 8(18.2 %) 0 8 
Total 44 0 44 
P (a):= 81.82%    P(e) = 81.82%     k=0.0000 
Table 7c.  Agreement between TST and QGTFIT in household contacts 
QFTGIT                              TST  
≥10mm <10mm Total 
≥0.35IU/ml 55(64.7 %) 5(5.9 %) 60  
<0.35IU/ml 8(9.4 %) 17(20 %) 25 
Total 63 22 85 
 P (a):= 84.71%      P (e) = 59.93%     k=0.6183     
The proportion (87.3%) of TB-gold positivity was significantly higher among TST positive 
individuals compared to TST negative (22.7%).  
Table 7d.  Agreement between TST and QFTGIT in Community controls 
QFTGIT                                                   TST 
≥10mm <10mm Total 
≥0.35IU/ml 26(44.8 %) 6(10.3 %) 32 
<0.35IU/ml 3(5.2 %) 23(39.7 %) 26 
Total 29 29 58 
P(a)=  84.48%        p(e)=  50.00%     k=0.6897       
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The proportion (89.7%) of TB-gold positivity was significantly higher among TST positive 
individuals compared to TST negative (20.7%) 
3.8. Estimation of Cut-off Values for TST in each Subgroup 
A receiver operator characteristic (ROC) curve analysis was used to estimate an optimum cut 
off value for TST in PTB patients, household contacts and community controls.  Using 
sputum smear as a reference test, skin test induration of ≥ 10 mm was found to be the 
optimum cut off value for TST in PTB patients (i.e. 100% sensitivity).  Increasing the cut off 
value to ≥ 15 mm reduced the sensitivity to 91.67%, while the specificity increased from 0% 
to 12.50%.  Using QFTGIT as the reference test, a skin test induration of ≥ 8 mm resulted in 
95.0% sensitivity and 68.0% specificity in household contacts.  When the cut off value 
increased to ≥ 10 mm or ≥ 15 mm skin test induration, the sensitivities of TST reduced to 
91.67% and 81.67%, respectively, while the specificity remained at 68.0%  At skin test 
induration ≥5 mm the sensitivity of TST  was 96.7% , while the specificity was 52%.  In 
community controls, at skin test indurations ≥  5 mm , 10 mm and 15 mm, the sensitivities 
were  found to be 90.6%, 81.3% and 65.6%, respectively, while the respective specificities 
were 80.8%, 88.5% and 100% in that order.  ROC curve for all participants as a whole and for 
each subgroup separately are represented below in figures 6a-d. 
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Figure 6a. ROC curve for all participants as whole 
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Figure 6b. ROC curve for PTB patients 
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Figure 6c. ROC curve for household contacts 
 
Figure 6d. ROC curve for community controls 
 
3.9. Accuracy of TST in Diagnosing Mtb Infection 
The overall accuracy of tuberculin skin test in the diagnosis of Mtb infection using smear 
microscopy as reference test for PTB patients and using QFTGIT as a reference test for both 
household contacts and community controls have been assessed (Table 8, 9, 10). In PTB 
patients, the sensitivity of TST was 100% using smear microscopy as a reference test. This is 
because all PTB patients were positive for both for the reference test and TST: In that case, 
there were no false negatives, false positives and true negatives.  In the case of household 
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contacts and community controls, sensitivity and specificity of TST were 91.7% vs.81.3% and 
68% vs.88.5% , respectively.  The positive and negative predictive values in both subgroups 
were 87.3% vs. 89.7% and 77.3% vs. 79.3%, respectively (Table 9, 10). Considering QFTGIT 
as a reference test, the sensitivity and specificity of TST in the diagnosis of mycobacterial 
infection in all participants were 91.4% and 67.8% respectively. The positive and negative 
predictive values were 86% and 78.4% (Table 8). 
Table 8. Accuracy of TST in diagnosing Mtb infection in all participants using QFTGIT as a 
reference test 
                      QFTGIT   
  Positive  Negative Total  
   
TST 
Positive  117 19 136 
Negative  11 40 51 
 Total  128 59 187 
Sensitivity = 91.4%  Specificity = 67.8% 
PPV =86%   NPV = 78.4%  
Table 9. Accuracy of TST in diagnosing Mtb infection in household contacts using QFTGIT 
as a reference test 
                   QFTGIT   
  Positive  Negative Total  
 
TST   
Positive  55 8 63 
Negative  5 17 22 
 Total  60 25 85 
Sensitivity = 91.7%       Specificity = 68% 
PPV = 87.3%   NPV = 77.3% 
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Table 10. Accuracy of TST in diagnosing Mtb infection among community controls using 
QFTGIT as a reference test  
                     QFTGIT   
  Positive  Negative Total  
  
TST 
Positive  26  3 29 
Negative  6 23  29 
 Total  32 26 58 
Sensitivity =81.3%            Specificity =88.5% 
PPV = 89.7 %   NPV = 79.3 % 
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Chapter 4. Discussion 
Tuberculin skin test, that measures cellular immune response against exposure to Mtb 
antigens, is more than 100 years old. Even though TST has many limitations, it has been 
widely used as a screening test for tuberculosis in many countries and has contributed a lot in 
terms of generating valuable epidemiological information on infection trends and on the 
magnitude of the disease. Many western countries are using TST for screening of TB among 
targeted groups including migrant people from high TB endemic countries of Africa and Asia, 
and people who reside for more than three months in high TB endemic countries.  Based on 
the recommendations of WHO and CDC (52) skin induration of ≥ 10mm is considered 
positive for Mtb infection and /or clinical TB. However, although TST positivity may be 
affected by local socio-economic, environmental, genetic and nutritional status of the 
population, no studies have been conducted in Ethiopia to assess the validity of this cut-off 
point. Therefore, the objective of this study was to compare the skin test induration among 
smear positive PTB patients, their household contacts and community controls in Ethiopia and 
to optimize the cut-off points for Mtb infection and clinical TB. 
To our knowledge, this is the first study in Ethiopia (one of the 22 high TB endemic 
countries) that compared TST in culture/smear confirmed PTB patients pulmonary patients, 
their household contacts, and community controls. In the present study all PTB patients, 
72.2% of house contacts, and only 46.7% had skin induration of ≥10mm, and the specificity 
of the test was found to be 100% in community controls. From the results of the present study, 
we can safely assume that TST can discriminate between Mtb infection and / or PTB from 
exposure to environmental mycobacteria. On the other hand, the present study is an agreement 
with the recommendation of WHO and CDC (52) that TST skin induration ≥10mm be used as 
a cut-off point to identify latently infected cases. The results also showed that 27% of the 
household contacts had skin of ≤10mm, 27% had between 10mm and 15mm, and 45% had 
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skin induration of ≥15mm. The results obtained could be a reflection of the heterogeneity of 
household contacts with regard to Mtb infection/disease. Some household contacts are 
exposed to Mtb infection but may be resistant to infection, some others could be infected but 
may not develop clinical disease, and some may be infected and progress to clinical disease. 
To achieve the objective of this study, potential factors that could, in one way or another, 
affect the size of skin test induration were excluded in as much as possible. We have 
excluded, for example, HIV positives, pregnant women, people with chronic medical illness 
(diabetes, cancer diseases), people who have been using immunosuppressing drugs (e.g. 
Steroids) for more than one month, and individuals with previous history of TB treatment. 
Since malnutrition could also suppress immunity, we have measured body mass index of all 
participants to see whether it had an effect on any of the participants. The two extreme ages 
were also excluded from the study, considering that they are generally less competent 
immunologically than the young adults.  
In our study, the prevalence of Mtb infection among household contacts of smear positive 
cases and Community controls (TST ≥10mm) were 64 (72.7%) and 35 (46.7%) respectively.  
Even though possible potential factors that could affect the size of TST were excluded, the 
prevalence of Mtb infection in both household contacts and community controls was yet very 
high; it was more than a quarter higher than the estimation that one-third of the world’s 
population is infected with Mtb. This implies that there is a high burden of TB infection in the 
society even though it might be difficult to generalize it for the whole population since the 
sample size is relatively small. A similar study in Gambia showed a relatively smaller 
prevalence of latent TB infection (57%) among household contacts of smear positive cases 
compared to our study (74).   
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On the other hand, there were also some from household contacts 12 (13.6%) and relatively 
high from community controls 33 (44%) who had no measureable skin test induration (0mm), 
referred to as anergy. Although the reasons are difficult to establish, anergy to TST could 
occur because of some chronic medical illness (e.g. diabetes Mellitus, cancer), some 
infectious diseases (e.g. HIV/AIDS, parasites), malnutrition, technical problems or the 
absence of tuberculosis infection (55,56). However, our results cannot be attributed to these 
factors because participants with these conditions have been excluded from the study. 
Fortunately, the same participants were also tested by QFTGIT and the result was similar with 
that of TST, especially in both household contacts and community controls. In fact, agreement 
between the two tests was assessed using Cohen’s Kappa coefficient and it was found that 
there was a good agreement between the two tests. This confirms indirectly that participants 
who had 0 mm skin test induration were also negative by QFTGIT. In that case, the skin 
induration of 0 mm among community controls and household contacts is probably due to the 
absence of infection with M. tuberculosis complex rather than anergy. Therefore, further 
testing to exclude anergy might be less important in this study (55, 56).  
 In the present study, 50 % of PTB patients were underweight (BMI<18.5kg/m
2
), which is a 
striking figure. Even though it is known that malnutrition is one of the factors in predisposing 
TB, much focus has not been given to it (75). More attention was given to HIV/AIDS 
prevention as one of the strategies in preventing TB. However, based on the finding of this 
study, malnutrition should also be given more attention in line with the prevention of 
HIV/AIDS in the fight against TB.  
Similarly, at the cut-off point QFTGIT ≥0.35IU/ml, the prevalence of Mtb infection among 
the household contacts and community controls were 64 (70.3%) and 32 (55.2%) respectively. 
Here, the results in both TST and QFTGIT are more or less similar, except that relatively 
higher proportion of community controls turned positive by QFTGIT than TST. Considering 
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participants who were tested by both TST and QFTGIT, at the cut-off points forTST≥10mm 
and QFTGIT≥0.35IU/ml, the prevalence of Mtb infection for household contacts and 
community controls were 55 (64.7 %) and 26 (44.8 %) respectively. The prevalence of Mtb 
infection among the household contacts is similar to that of what was found with the 
prospective cohort study conducted in Netherland among immigrant close contacts for smear 
positive PTB patients, and the study participants also had similar inclusion and exclusion 
criteria as well as tests (Sputum, TST, QFTGIT, Chest x- ray), but participants were followed 
up for two years (76).  However, study done in Italy on immigrants from high TB burden 
countries using the same tests showed lower prevalence of latent TB infection compared to 
our finding (77) 
In the present study, the prevalence of Mtb infection after combining the two tests was similar 
in both contacts and community controls with that of when the two tests are considered 
separately whereas  lower proportion of  patients were positive by QFTGIT compared to that 
of  by TST. Kappa analysis was done to see whether there is an agreement between the two 
tests in patients and it was found that there was poor agreement (kappa = 0.000). The 
explanation for this could be that there was some PTB patients 8 (18.2%) who were negative 
by QFTGIT while all of them were positive by TST (TST≥10mm). Apart from the poor 
agreement observed in TB patients, the two tests have showed similar diagnostic performance 
in the diagnosis of Mtb infection, especially in household contacts and community controls. 
This finding is similar with a study conducted in Ethiopia on healthy young adults in 
2008/2009 in which both TST and QFTGIT were compared (78). 
Mean values of TST and IFN- were compared among the subgroups of the study 
participants. The difference in the mean size of TST in PTB patients and household contacts, 
in PTB patients and community controls as well as in household contacts and community 
controls were highly significant (p<0.05). Similarly, the difference in the mean level of IFN- 
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in PTB patients and community controls as well as in household contacts and community 
controls were also highly significant (p<0.05). However, the difference in the mean level of 
IFN-y in PTB patients and household contacts was not significant. The baseline 
characteristics like age, sex, BCG vaccination, nutritional status and use of substances (khat, 
cigarette, and alcohol) had no significant effect on the mean level of IFN-y. However, being a 
male in community controls, having a normal weight in PTB patients as well as having BCG 
vaccination in all participants is associated with higher skin size indurations. The number of 
participants 89 (39.7%) who had BCG scar in this study were small in number compared to 
the 2010 WHO report on BCG vaccination coverage for Ethiopia (69%).  The reasons for this 
big difference could be that BCG vaccination was intensified in recent years in Ethiopia, and 
the age groups included in this study didn’t include children below 15 years who assumed to 
have higher BCG coverage. This number could also be underestimated as there were a lot of 
participants with indeterminate results. Majority of participants were not originally from 
Addis Ababa (61.6%) and very few of them had BCG scar compared to those who were born 
in Addis Ababa. 
Regarding optimizing the cut-off points of TST in each subgroup of participants, a receiver 
operating characteristic  (ROC) curve analysis was used. In the present study, considering 
sputum culture as reference test for TB patients, skin test induration of ≥ 10 mm was found to 
be the optimal cut off value for TST (i.e. 100% sensitivity) whereas for household contacts 
and community controls even though as of today there is no standard test for the diagnosis of 
latent TB infection, here we used QFTGIT as a reference test to optimize the cut-off points of 
TST in these subgroups.  For example, TST ≥ 8 mm resulted in 95.0% sensitivity and 68.0% 
specificity in household contacts whereas increasing TST to ≥ 10 mm or ≥ 15 mm resulted in 
sensitivities of 91.67% and 81.67% respectively, but specificities were 68% at both cut-off 
points.  In community controls, at skin test indurations ≥  5 mm , 10 mm and 15 mm, the 
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sensitivities were  found to be 90.6%, 81.3% and 65.6%, respectively, while the respective 
specificities were 80.8%, 88.5% and 100% in that order. This study was conducted with the 
expectation that it would result in higher cut- off values than what has been set by WHO. In 
case of community controls, both those who had no measurable skin size induration and those 
who had TST ≥10 mm were almost equal (around 45 % each).This could be a problem in 
deciding the optimal cut- off value in this group. Moreover, since the sample size in this study 
was relatively small, it could also affect determining the optimal cut- off points. 
Despite its limitations, TST is widely used for the diagnosis of latent TB infection many 
countries of Western Europe, Canada, Japan and USA, with different approaches (79).  For 
instance, according to the UK National Institute of Health and Clinical Excellence, positive 
TST and IGRAs test indicate latent infection. In the USA and Japan, it is recommended that 
IGRAs should replace TST (79). A recent study in Norway has suggested "IGRA-only" as a 
desirable screening strategy despite its limitations in serial testing, due to the high numbers of 
discordant TST positive/IGRA negative results in HCW. Thus, the authors suggested the need 
for proper guidelines for TB screening to secure accurate diagnosis of LTBI and offer proper 
treatment and follow-up in Norway (80). Generally, a growing number of guidelines 
addresses that the use of   IGRAs is increasingly recommended, primarily in low incidence 
settings. Because of its lower specificity, IGRAs are not primarily recommended in high 
incidence settings. 
IFN-γ-based tests have been developed as an alternative immunodiagnostic approach to the 
TST. Comparing the diagnostic performance of IFN-γ- based tests with the TST test is 
hindered by lack of standard reference test for latent infection that makes it impossible to 
directly measure sensitivity and specificity. However, the results of the present study indicate 
a good agreement between TST and IFN-γ test. In this regard, several studies have found that 
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discordance between the TST and IFN-g-based tests is due to BCG vaccination (79), for 
which we have controlled in the present study.  
4.1. Limitations of the Study 
 Shortage of QFTGIT kit: Because of the shortage of QFTGIT test kit, some of the 
study participants, especially the community controls, didn’t get the chance to be 
tested by QFTGIT. 
 Difficulty of identifying BCG scars: Some participants had more than one scar which 
made it difficult to differentiate the one from the other, and some had one scar which 
was not typical for BCG scar. Because of this, many of the participants had to be 
labeled as indeterminate 
 Relatively less number of males participated in community controls. The aim was to 
have equal number of males and females in each subgroup and among all participants, 
but under recruiting of community controls, it was found that males were less 
voluntarily to participate in the study.  
 Shortage of finance and time 
 Some participants failed to take PPD injection 13 (5.8 %) and some 5 (2.4%) failed to 
appear for the reading the skin test induration. 
 Some participants were not interested to take chest X-ray5 (5%). 
 The number of AFB culture was not done as originally planned due to inaccessibility 
of the lab due natural disaster? 
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4.2. Conclusion 
TST is the standard tool to detect latent TB infection in many developed countries, and TST 
skin induration of ≥10mm is the cut-off point to discriminate infection from non-infection. 
Results of the present study are in agreement with the recommendation made WHO and CDC 
on TST cut-off point TST that discriminates between Mtb infection and non-infection. 
Moreover, both TST and QFTGIT showed, more or less, similar diagnostic performance in 
demonstrating of Mtb infection. The majority (91.7%) of smear positive TB patients had skin 
test induration ≥ 15 mm. Moreover, the specificity of the TST was found to be 100% at skin 
test induration ≥15 mm in community controls who had no known exposure to TB. Since, a 
test with high specificity is more useful in areas with a high prevalence of disease, skin test 
induration ≥ 15 mm seems to be optimal for suspecting active TB and recommending chest X-
ray in individuals without symptoms suggestive of active TB, while skin test induration ≥ 10 
mm seems optimal to suggest Mtb infection in household contacts of TB patients.  
4.3. Recommendation 
Further study with larger sample size and follow up for at least two years can give better 
result with this type of study.  
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6. Appendices 
6.1. Appendix 1 
Participants’ information sheet 
Background information of the study 
Tuberculosis (TB) is one of the major causes of health problems in Ethiopia. However, all 
individuals who are infected with the bacteria that cause TB do not develop the disease.     
Several developing countries still depend on tuberculin skin test (TST) to screen latent TB 
infection. Therefore, this study is designed to evaluate/compare cut-off points of TST set by 
WHO in TB patients, their close contacts and community in Ethiopia. This study will be 
conducted   in Addis Ababa at six health centres that are selected randomly. 
The study has been ethically approved by the Norwegian Ethical Committee, the Institutional 
Review Board (IRB) of the Aklilu Lemma Institute of Pathobiology, Addis Ababa University 
and the National Research Ethics Committee of Ethiopian Science and Technology Ministry. 
Therefore, youand/or your family are voluntarily requested to participate in the study after 
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understanding the objective of the study, the risk and discomfort, benefits, incentives and 
confidentiality. Your choice (your parent`s and your choice in case of individuals under 18 
years) not to participate in the study will have no any effect on the care you will be provided 
from the health facility and hence you still receive the same treatment as others without any 
prejudice. 
Objective of the study  
The main objective of the study is to optimize the cut-off point of TST for the diagnosis of 
latent TB in Ethiopia 
Study Participants   
In this study, 78 PTB patients, 78 contactsand 78 individuals from community (age 15 and 
above years, both male and female) will participate. PTB patients who are critically ill, 
patients on TB treatment; HIV positive cases/other co-morbidity; pregnant women and 
children under 15 years will not participate in the study.  
Samples Required and Examinations/Research 
 If you and/or your parent (in case individuals under 18 years) agree to participate in the 
study, you will provide sputum, blood, and stool samples for various examinations/research 
purposes upon entry. You will also be injected with tuberculin PPD and diagnosed by chest 
radiograph. 
a) Sputum: if you are suspected of pulmonary TB by your doctor and your doctor 
requests for sputum examination as the routine part of your diagnosis, you will 
provide sputum sample three times (i.e. on the first day of your visit to a health facility 
and the next morning). A portion of your sputum will be examined by direct smear 
microscopy on the same day of delivery and you will get the results through your 
doctor within two days. The rest of the sputum will be transported to the ALIPB 
laboratory for further examination by culture method and the results will be 
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communicated within two months.  If you are found positive for TB by the direct 
smear examination, you will soon start anti-TB treatment. If you are not found 
positive, your doctor will decide your treatment based on additional investigations like 
chest radiograph and TST even before the result of culture.  
b) Blood:  3 ml (approximately 1 table spoonful) venous blood will be collected from 
your hand into three test tubes using only one needle for TB-gold test assay. This test 
cannot be used for the diagnosis of active TB, and hence treatment will be not given 
based on the result of blood test. However, the results will be used for the research 
purpose.  
c) Skin test: 0.1 ml Tuberculin PPD will be injected intradermal into the volar aspect of 
the forearm.  The results (size of skin induration) will be measured between 48 to 72 
hours. Skin test will be done for all the study participants; however, the skin test result 
alone cannot be used for diagnosing active TB and treatment. However, you will be 
advised to consult the nearest health facilities in case you develop signs/symptoms 
suggestive of active TB.       
d) Stool: Stool sample will be collected to examine for intestinal parasitic infection by 
direct and concentration methods. The results of the direct method will be 
communicated to you through your physician on the same day and if you are found 
positive for intestinal parasitic infection, you will get appropriate free treatment. The 
main purpose for stool examination is to investigate the effect of intestinal parasitic 
infection(s) on your immunity against TST and TB-gold test assay. 
e) HIV testing: If you agree to participate in this study,   you will be provided with 
counselling for HIV testing and you are strongly advised to know your status. 
However, your decision not to be tested and know your status is respected. HIV 
testing will be done by rapid diagnostic test using finger prick blood sample before 
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taking sputum, blood or stool samples.  If you are found positive for HIV infection, 
you will be referred to the nearest HIV clinic for additional examination like  CD4 
count and ART 
Risk and Discomfort  
 We do not expect a definitive risk as a result of sample collection or participating in the 
study.  However, during blood collection and tuberculin PPD injection, you may experience 
some pain and discomfort. In all cases, if you develop any complication, you will be provided 
appropriate treatment in the local health facility free of charge and the cost will be covered by 
the project.  
Benefits   
Whether you participate in the study or not, you will get the routine health services rendered 
by the health facility you visited. This means, there is no such a direct benefit as a result of 
your participation in the study. However, additional investigations like sputum culture and 
stool examination are your benefits from the study. TB patients contacts cases who manifest 
clinical sign and symptoms of pulmonary TB (undiagnosed), but diagnosed for TB during the 
survey will directly benefit from the study.  
Incentives  
You will not be given any incentive to participate in the study.  
Confidentiality  
Information related to your name will be treated strictly confidential. Names and identifiers 
will be coded and deleted after data collection and therefore data will be treated anonymously 
for communication of results. Informed consent forms and questionnaires will be left behind 
in a locked cabinet in Ethiopia and will be destroyed after a year following termination of the 
data collection. The results of your clinical and laboratory examination will not be shown to 
anyone except the research team and your doctor.  
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6.2. Appendix 2 
Study Participant Consent Form  
Name of the participant: ___________________________________Age______Sex___ 
Code___________________Study site/Health facility ______________________________  
I confirm that I, and my parent (s) (in case individuals under 18 years) have been given 
adequate information about the research project, Optimization of cut-off point of tuberculin 
skin test in the diagnosis of tuberculosis in Ethiopia.I and/or my parent (in case individuals 
under 18 years) have been requested to provide sputum, 3 ml of venous blood, skin test and 
stool samples at the time of entry. The researchers informed and/or my parent (in individuals 
under 18 years) that there is no major risk associated with participating in the study or 
providing the requested samples. I and/or my parent have also understood that the results of 
clinical and laboratory diagnosis   will be used for research purposes and the information 
related to myself/my family will be kept strictly confidential. I and/or my parent well 
informed that participation in the study is fully voluntary and I and/or my family can 
withdraw anytime without giving any reason. Moreover, I am and/or my family fully aware 
that non-participation in this project will not subject me or my family to any health service 
denial from this health facility either now or in the times to come. I and/or my parent confirm 
that all the information provided to me is very clear and has been conveyed by the language 
that I fully understand. Finally, I and/or my parent  declare that I have been given enough time 
to deliberate before I and/or my parent  agree to participate in the study, and I and/or my 
parent (in case  individuals under  18 years) signed this informed consent. 
Name of participant...........................................................Signature........................Date……  
Name of parent/guardian _________________________Signature……………date……  
Name of the physician obtaining consent................................................ signature:……… date  
Name of  witness …………………………………….Signature………………Date………….  
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Name and address of Contact person: 
Kebede C. Shero, or Dr. MengistuLegesse 
Tele: 251-11-276-30-91, Mobile 911345908, P.O. Box, 1176 
Aklilu Lemma Institute of Pathobiology, Addis Ababa University, Addis Ababa, Ethiopia  
6.3. Appendix 3 
Questionnaire for pulmonary TB patients 
Health Center………………………………………………… 
InclusionCriteria 
1. Age above 15 yearsold 
2. People who are volunteer to participate 
3. Non-pregnant women 
4. Not seriously sick patients 
5. Individuals who do not have a problem of allergy 
6. HIV negative individuals 
7. People who do not have cancer or diabetes 
8. People who are not on immune suppressive drugs such  as steroids 
Socio-demographic information 
1.Name of the participant………………………..Age…………Sex……………… 
2. Participant’s code………………………………………………………………... 
3. Address of the participant: Sub-city……………Woreda……….Kebele………. 
    House Number…………………. Telephone Number………………………….. 
4. Marital Status Single 1 
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 Married 2 
 Divorced 3 
 Partnership 4 
 Widow 5 
5. Religion Orthodox 1 
 Catholic 2 
 Protestant 3 
 Muslim 4 
 Others 5 
6. Ethnicity Amhara 1 
 Oromo 2 
 Tigre 3 
 Gurage 5 
 Others 6 
7. Level ofEducation Cannotwrite and read 1 
 Canwrite and read 2 
 Educated:  
 Primary 
  Secondary 
 Higher education 
 
 
3 
4 
5 
8. Occupation Merchant 1 
 Employee 2 
 Unemployed 3 
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 Student 4 
 House Wife 5 
 Others 6 
 
9. Place of birth………………0. Addis Ababa  1. Others 
10. How long have you been in Addis Ababa?...............................................Years 
11. How many family members do you have? 1. One 2. Two to five  3. More than five 
12. How many of them are above 15 years old? 1. One 2. Two to five 3. More than five 
                   Clinical Information 
13.  Form of PTB… 1. Newly diagnosed smear positive PTB  2. Newly diagnosed negative   
PTB  3. Relapse 4.Treatment failure (smear positive) 
14. Onset of TB…..1. <6weeks  2. 6weeks-3months   3. 3-6months 4.>6months 
 
15.Which of the following 
symptoms do you have? 
Yes(0) No (1) 
Cough lasting for ≥ two 
weeks 
  
Sputumwithoutblood   
Bloodysputum   
Nightsweating   
Fever   
Loss ofappetite   
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Shortness o breath   
Weight loss over the last six 
months  
  
Chestpain   
Weakness   
Others   
 
16. Have you ever been treated for TB before?  0. Yes  2. No 
17. Have you ever been vaccinated with BCG?   0. Yes    1. No    2. Don’t know 
If yes, look for a scar?   0. Yes   1.No   2. Indeterminate 
18. Have you ever had a Mantua test for TB infection?  0. Yes   1. No  2.Don’t know 
19. Weight………………(Kilograms) Height………(Centimeters) BMI………..Kg/m2 
20. Chest X-ray     1. Normal       2. Abnormal 
21. Do you use khat?  0. Yes       1. No 
22. Do smoke cigarette?  0. Yes     1. No    If yes, how much per day ………………. 
23. Do you drink alcohol?  0. Yes   1 No    If yes, how much per day………………. 
24. Date of tuberculin skin test……………..time……………………………… 
25. Skin test result………………………….mm, after………………….hours 
26. AFB result and count (If PTB suspected)………………………………….. 
27. Culture result………………………………………………………… 
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28. TB Gold test result: binary  1. Positive 2. Negative 
                                      : OD value………………………………………. 
29. HIV test result    1. positive      2. Negative 
30. Stool test result…………………………………………………………….. 
Date of investigation…………………………………………………………… 
Investigated by………………………………….. Signature…………………… 
6.4. Appendix 4 
Questionnaire for assessment of risk for tuberculosis infection 
Health Center………………………………………………… 
Inclusion Criteria 
1. Age above 15 yearsold 
2. People who are volunteer to participate 
3. Non-pregnant women 
4. Nof seriously sick patients 
5. Individuals who do not have a problem of allergy 
6. HIV negative individuals 
7. Individuals who have contact history of T 
8. People who do not have cancer or diabetes 
9. People who are not on immune suppressive drugs such  as steroids 
10. People who had no previous history of tuberculosis?  
Socio-demographic information 
1.Name of the participant………………………..Age…………Sex……………… 
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2. Participant’s code………………………………………………………………... 
3. Address of the participant: Sub-city……………Woreda……….Kebele………. 
    House Number…………………. Telephone Number………………………….. 
    Patient’s name………………………………… and code………………………. 
4. Marital Status Single 1 
 Married 2 
 Divorced 3 
 Partnership 4 
 Widow 5 
5. Religion Orthodox 1 
 Catholic 2 
 Protestant 3 
 Muslim 4 
 Others 5 
6. Ethnicity Amhara 1 
 Oromo 2 
 Tigre 3 
 Gurage 5 
 Others 6 
7. Level ofEducation Cannotwrite and read 1 
 Canwrite and read 2 
 Educated:  
 Primary 
 
3 
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  Secondary 
 Higher education 
 
4 
5 
8. Occupation Merchant 1 
 Employee 2 
 Unemployed 3 
 Student 4 
 House Wife 5 
 Others 6 
 
9. Residence………………0. Addis Ababa  1. Others 
10. How long have you been in Addis Ababa?...............................................Years 
Clinical Information 
1. What is your relation with the TB patient?................................................................... 
1. Wife           2. Husband       3. Daughter     4. Son      5. Mother     6. Father    7. 
Other 
2. How long have you been with the TB patient since he/she became sick?..................... 
3. Do you live in the same house with the patient?      1.  Yes      2. No 
4. How many rooms does the house have?......................and window………… 
5. Do you sleep in the same room with the patient?  1. Yes      2. No 
6. Do you sleep in the same bed with the patient?    1.Yes2.No 
7. If no, for question No 14, how many hours do you spend with the patient per 
day……… 
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8. Which of the 
following symptoms 
do you have? 
Yes(0) No (1) 
Cough lasting for ≥ two 
weeks 
  
Sputumwithoutblood   
Bloodysputum   
Nightsweating   
Fever   
Loss ofappetite   
Shortness o breath   
Weight loss over the last six 
months  
  
Chestpain   
Weakness   
Others   
 
9.  Have you ever been vaccinated with BCG?   0. Yes    1. No    2. Don’t know 
If yes, look for a scar?   0. Yes1.No   2. Indeterminate 
10.  Have you ever had a Mantua test for TB infection?  0. Yes   1. No  2.Don’t know 
If yes, what was the result?.................................................................................... 
11. Weight……………………………..(Kilograms)  Height………(Centimeters) 
12. ChestX-ray     1. Normal       2. Abnormal 
13. Do you use khat?  0. Yes       1. No 
89 
 
14. Do smoke cigarette?  0. Yes     1. No    If yes, how much per day ………………. 
15. Do you drink alcohol?  0. Yes   1 No    If yes, how much per day………………. 
16.  Date of tuberculin skin test……………..time……………………………… 
17.  Skin test result………………………….mm, after………………….hours 
18. AFB result and count (If PTB suspected)………………………………….. 
19. Cultureresult………………………………………………………………. 
20.  TB Gold test result………………………………………………………… 
21. HIV test result    1. positive      2. Negative 
22. Stool test result…………………………………………………………….. 
Date ofinvestigation……………………………………………………………….. 
Investigated by…………………………………..Signature…………………………… 
6.5. Appendix 5 
Questionnaire for community controls 
Inclusion Criteria 
1. Age above 15 yearsold 
2. People who are volunteer to participate 
3. Non-pregnant women 
4. No seriouslysickpatients 
5. Individuals who do not have a problem of allergy 
6. HIV negative individuals 
7. Individuals who do not have  contact history of TB in the last two years 
8. People who do not have cancer or diabetes 
9. People who are not on immune suppressive drugs such  as steroids 
10. People who had no previous history of tuberculosis?  
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11. No history of participation in the clinical trial for vaccine or drugs in the last six 
months 
Socio-demographic information 
1.Name of the participant………………………..Age…………Sex……………… 
2. Participant’s code………………………………………………………………... 
3. Address of the participant: Sub-city……………Woreda……….Kebele………. 
House Number…………………. Telephone Number………………………….. 
4. Marital Status Single  
 Married  
 Divorced  
 Partnership  
 Widow  
5. Religion Orthodox  
 Protestant  
 Catholic  
 Muslim  
 Others  
6. Ethnicity Amhara  
 Oromo  
 Tigre  
 Gurage  
 Others  
7. Level ofEducation Cannotwrite and read  
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 Canwrite and read  
 Educated. (Primary, 
Secondary, Diploma, Degree) 
 
8. Occupation Merchant  
 Employee  
 Unemployed  
 Student  
 House Wife  
 Others  
 
9. How long have you been in Addis Ababa?...............................................Years 
10. How do you live?   1. In own house   2.  Rented 
11. How many rooms does the house have... ……and window………………….  
12. How many are you in the same bed room?.......................................................... 
13. What is approximately your monthly income?.............................................. 
Clinicalinformasjon 
18. Which of the following 
symptoms do you have? 
Yes No 
Cough lasting for ≥ two 
weeks 
  
Sputumwithoutblood   
Bloodysputum   
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Nightsweating   
Fever   
Loss ofappetite   
Shortness o breath   
Weight loss over the last six 
months  
  
Chestpain   
Weakness   
Others   
 
19. Have you ever been vaccinated with BCG?   1. Yes    2. No    3. Don’t know 
      If yes, look for a scar?   1. Yes   2.No   3. Indeterminate 
20. Have you ever had a Mantua test for TB infection?  1. Yes   2. No   3. Don’t know 
      If yes, what was the result?.................................................................................... 
21. Do you chew khat?          1. Yes          2. No 
22. Do you smoke?                1. Yes          2. No 
23. Do you drink alcohol       1. Yes        2. No 
24. Weight…………………………….. (Kilograms) Height……… (Centimeters) 
25. Date of tuberculin skin test……………..time……………………………… 
26. Skin test result………………………….mm, after………………….hours 
27. TB Gold test result………………………………………………………… 
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28. Stool test result…………………………………………………………….. 
29. Chest X-ray     1. Normal       2. Abnormal 
Date of investigation…………………………………………………………… 
Investigate by…………………………………..Signature……………………… 
 
 
 
